WO2007146104A3 - Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use - Google Patents

Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use Download PDF

Info

Publication number
WO2007146104A3
WO2007146104A3 PCT/US2007/013480 US2007013480W WO2007146104A3 WO 2007146104 A3 WO2007146104 A3 WO 2007146104A3 US 2007013480 W US2007013480 W US 2007013480W WO 2007146104 A3 WO2007146104 A3 WO 2007146104A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
methods
substrates
antiplasmin
cleaving enzyme
Prior art date
Application number
PCT/US2007/013480
Other languages
French (fr)
Other versions
WO2007146104A2 (en
Inventor
Patrick A Mckee
Kyung N Lee
Kenneth W Jackson
Victoria J Christiansen
Original Assignee
Patrick A Mckee
Kyung N Lee
Kenneth W Jackson
Victoria J Christiansen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick A Mckee, Kyung N Lee, Kenneth W Jackson, Victoria J Christiansen filed Critical Patrick A Mckee
Priority to CA002658331A priority Critical patent/CA2658331A1/en
Priority to MX2008015649A priority patent/MX2008015649A/en
Priority to JP2009514389A priority patent/JP2009539853A/en
Priority to EP07809392A priority patent/EP2038653A4/en
Priority to AU2007258495A priority patent/AU2007258495A1/en
Publication of WO2007146104A2 publication Critical patent/WO2007146104A2/en
Publication of WO2007146104A3 publication Critical patent/WO2007146104A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention is directed toward inhibitors of antiplasmin cleaving enzyme for use in various therapies related to fibrin and α2-antiplasmin, and to substrates of APCE, which may be used, for example, in screening methods for identifying such inhibitors. The present invention is further directed to methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the rations of types of plasma α2-antiplasmin.
PCT/US2007/013480 2006-06-07 2007-06-06 Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use WO2007146104A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002658331A CA2658331A1 (en) 2006-06-07 2007-06-06 Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
MX2008015649A MX2008015649A (en) 2006-06-07 2007-06-06 Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use.
JP2009514389A JP2009539853A (en) 2006-06-07 2007-06-06 Antiplasmin cleaving enzyme substrates and inhibitors and uses thereof
EP07809392A EP2038653A4 (en) 2006-06-07 2007-06-06 Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
AU2007258495A AU2007258495A1 (en) 2006-06-07 2007-06-06 Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81156806P 2006-06-07 2006-06-07
US60/811,568 2006-06-07
US83636506P 2006-08-08 2006-08-08
US60/836,365 2006-08-08

Publications (2)

Publication Number Publication Date
WO2007146104A2 WO2007146104A2 (en) 2007-12-21
WO2007146104A3 true WO2007146104A3 (en) 2008-10-16

Family

ID=38832396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013480 WO2007146104A2 (en) 2006-06-07 2007-06-06 Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use

Country Status (6)

Country Link
EP (1) EP2038653A4 (en)
JP (1) JP2009539853A (en)
AU (1) AU2007258495A1 (en)
CA (1) CA2658331A1 (en)
MX (1) MX2008015649A (en)
WO (1) WO2007146104A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
EP3555627B1 (en) 2016-12-14 2023-11-22 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309774B2 (en) * 2003-02-07 2007-12-18 The Board Of Regents Of The University Of Oklahoma Antiplasmin cleaving enzyme

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEE ET AL.: "A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion", BLOOD, vol. 103, no. 10, May 2004 (2004-05-01), pages 3783 - 3788, XP002394321 *
LIND B. ET AL: "A novel missense mutation in the human plasmin inhibitor (alpha2-antiplasmin) gene associated with a bleeding tendency", BRITISH JOURNAL OF HAEMATOLOGY, vol. 107, 1999, pages 317 - 322, XP008101968 *
See also references of EP2038653A4 *

Also Published As

Publication number Publication date
EP2038653A2 (en) 2009-03-25
MX2008015649A (en) 2009-03-25
CA2658331A1 (en) 2007-12-21
WO2007146104A2 (en) 2007-12-21
AU2007258495A1 (en) 2007-12-21
EP2038653A4 (en) 2010-04-21
JP2009539853A (en) 2009-11-19

Similar Documents

Publication Publication Date Title
WO2006078752A3 (en) Inhibitors of dna methyltransferase
WO2007026251A8 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2008153753A3 (en) Compositions and particles containing cellulosic fibers and stabilized- and/or activated- urease inhibitors, as well as methods of making and using the same
WO2006034235A3 (en) Substituted quinoline and quinazoline inhibitors of quinone reductase 2
WO2007120478A3 (en) Glycomic patterns for the detection of disease
WO2006023866A3 (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
WO2008009639A3 (en) New indications for direct thrombin inhibitors
WO2006060737A3 (en) Mitotic kinesin inhibitors
WO2007050795A3 (en) Transglutaminase inhibitors and methods of use thereof
MX2010004630A (en) Method and apparatus for monitoring spatial fibrin clot formation.
WO2007048067A3 (en) C-kit oncogene mutations in melanoma
WO2005076854A3 (en) Pyrimidinone compounds useful as kinase inhibitors
AU2003272800A1 (en) Methods for identifying inhibitors of botulinum neurotoxins
WO2007133773A3 (en) Identification of cdki pathway inhibitors
WO2009017670A3 (en) Ras-mediated epigenetic silencing effectors and uses thereof
EP1808493A3 (en) Substrates and methods for assaying deubiquitinating enzymes activity
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors
WO2007146104A3 (en) Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
WO2012034130A3 (en) Methods and compositions for nucleic acid detection
WO2007136857A3 (en) Hox compositions and methods
WO2007117419A3 (en) Methods and compositions relating to post-prolyl cleaving enzyme inhibitors
WO2007089542A3 (en) Systems and methods of analyzing nucleic acid polymers by using particle beams
WO2006037102A3 (en) Methods for identifying polymerase inhibitors
WO2009100254A3 (en) Protein tyrosine phosphatase inhibitors
WO2001007579A3 (en) Methods and compositions for determining enzymatic activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780029416.4

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07809392

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009514389

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/015649

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007258495

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2007809392

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2658331

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2007258495

Country of ref document: AU

Date of ref document: 20070606

Kind code of ref document: A